详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

89| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol,Tong Med Coll,Tongji Hosp,Dept Neurosurg,Wuhan,Peoples R China [2]Tianjin Med Univ, Tianjin Key Lab Med Epigenet, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Cell Biol, Tianjin, Peoples R China [3]Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China [4]Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China

出处：

DOI：

ISSN：

关键词： glioblastoma immune checkpoint CD47-SIRPα tumor-associated macrophages microglia glioblastoma microenvironment

摘要：

Glioblastoma Multiforme (GBM) is the most common and aggressive form of intracranial tumors with poor prognosis. In recent years, tumor immunotherapy has been an attractive strategy for a variety of tumors. Currently, most immunotherapies take advantage of the adaptive anti-tumor immunity, such as cytotoxic T cells. However, the predominant accumulation of tumor-associated microglia/macrophages (TAMs) results in limited success of these strategies in the glioblastoma. To improve the immunotherapeutic efficacy for GBM, it is detrimental to understand the role of TAM in glioblastoma immunosuppressive microenvironment. In this review, we will discuss the roles of CD47-SIRP alpha axis in TAMs infiltration and activities and the promising effects of targeting this axis on the activation of both innate and adaptive antitumor immunity in glioblastoma.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2018]版：

Q2 IMMUNOLOGY

最新[2024]版：

Q1 IMMUNOLOGY

影响因子： 5.9 最新[2024版] 6.8 最新五年平均 4.716 出版当年[2018版] 5.789 出版当年五年平均 5.511 出版前一年[2017版] 5.085 出版后一年[2019版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol,Tong Med Coll,Tongji Hosp,Dept Neurosurg,Wuhan,Peoples R China

通讯作者：

通讯机构： [2]Tianjin Med Univ, Tianjin Key Lab Med Epigenet, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Cell Biol, Tianjin, Peoples R China [3]Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China [4]Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Targeting UDP-α-D-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth [2]Targeting UDP-alpha-D-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth [3]Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment [4]Signal Pathways Involved in the Interaction Between Tumor-Associated Macrophages/TAMs and Glioblastoma Cells [5]Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma [6]Aquaproin1 mediated tumor associated microglia/macrophages polarization in gliomas [7]EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment [8]The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma [9]Macrophages facilitate tumor cell PD-L1 expression via an IL-1 beta-centered loop to attenuate immune checkpoint blockade [10]TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling